Search results

Technologies 2

• Targeted EPO: Safely Normalizing Oxygen Delivery in a Broad Range of Disease Conditions
  General Biologics commercializes Targeted EPO as a first-in-class fusion protein therapeutic for the treatment of life-threatening and limiting hypoxia in various disease conditions, including COPD, cystic fibrosis, COVID-19, and severe anemias, such as in patients with kidney failure.
• Omniphobic material that empowers a new category of medical devices
  Cerulean Scientific is using our thin layer perfluorocarbon technology to develop medical devices that resist clotting, obstruction and infection, reducing patient suffering and lowering healthcare costs for the 10% of the population treated with an implantable medical device.

News 7

View all

• Community
  
  Adama Sesay on Solving Problems with Sensors and Microsystems
  March 30, 2023
• Research Spotlights
  
  Portable, injectable clotting agent could treat trauma victims on the front lines
  July 31, 2020
• Press Release
  
  Platelet “Decoys” Outsmart Both Clots and Cancer
  February 13, 2019

Multimedia 1

• 

  Video/Animation
  Bioinspired Blood Repellent Coating
  In this video, Wyss Institute Founding Director Don Ingber, Core Faculty member Joanna Aizenberg, Staff Scientist Dan Leslie and Postdoctoral Fellow Anna Waterhouse explain how a coating they developed using FDA-approved materials could prevent blood clotting in medical devices without the use of blood thinners. Credit: Wyss Institute at Harvard University